Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Severe relapses under fingolimod treatment prescribed after natalizumab.
The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.
[New and emerging treatments for multiple sclerosis].
Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes.
Repeated sugammadex usage in a patient with multiple sclerosis: a case report.
A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort.
A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin.
Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis.
Cognitive impairment is correlated with reduced quality of life in patients with clinically isolated syndrome.
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.
Compromised motor imagery ability in individuals with multiple sclerosis and mild physical disability: An ERP study.
CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis.
Induction of intestinal Th17 cells by segmented filamentous bacteria.
Multiple sclerosis: Brain volume loss strengthens disease measure.
Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.
TET2 gene expression and 5-hydroxymethylcytosine level in multiple sclerosis peripheral blood cells.
Leg spasticity and ambulation in multiple sclerosis.
Neuromyelitis optica.
Endovascular Treatment of Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: A retrospective study.
Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation.
Modulation of Glutamate Transport and Receptor Binding by Glutamate Receptor Antagonists in EAE Rat Brain.
High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010).
Study protocol: To investigate effects of highly specialized rehabilitation for patients with multiple sclerosis a randomized controlled trial of a personalized, multidisciplinary intervention.
A technical approach to dissecting and assessing cadaveric veins pertinent to chronic cerebrospinal venous insufficiency in multiple sclerosis.
Switch-associated protein 70 antibodies in multiple sclerosis: relationship between increased serum levels and clinical relapse.
Pages
« first
‹ previous
…
291
292
293
294
295
296
297
298
299
…
next ›
last »